Based on this knowledge, we postulated that melanoma cells from patients responding to immunotherapy should be sensitive to the anti-proliferative and pro-apoptotic effects of IFNγ and that continuous cytokine exposure should select for the outgrowth of IFNγ-resistant tumour subclones. The gene discussed is IFNG; the disease is melanoma.